T47D/S2 Cell Line
Invented by Dr Anne Lykkesfeldt at Danish Cancer Society
T47D/TR-1 Cell Line
Invented by Dr Anne Lykkesfeldt from Danish Cancer Society
Invented at Danish Cancer Society
- Datasheet
- References (8)
- Inventor Info
Info
| Catalogue Number | 152108 |
| Antigen/Gene or Protein Targets | Oestrogen receptor |
| Parental Line | T47D/S2 |
| Host | Human |
| Tissue | Breast |
| Disease Keywords | Breast carcinoma, tamoxifen resistant |
| Model | Tumour line |
| Relevance | The T47D/TR-1 Cell line is a breast cancer cell line resistant to tamoxifen. Antiestrogen resistance is a major problem in breast cancer treatment. Therefore, the search for new therapeutic targets and biomarkers for antiestrogen resistance is crucial. This cell line allows the study of the mechanisms involved in tamoxifen resistant breast cancer cell growth. |
| Production Details | The T47D/TR-1 cell line has been established by long term treatment of T47D/S2 cells with 1 µM tamoxifen. Clonal selection was performed in medium without tamoxifen. After growth in presence of 1 µM tamoxifen for 10 months, the growth rate was similar to the parental cells. |
| Research Area | Cancer, Drug Discovery & Development |
| Recommended Growing Conditions | Phenol red free RPMI 1640 + 2% FCS + glutamax + 8µg Insulin/ml + 1 uM tamoxifen |
| Notes |
T47D/TR-1 cells are ER alpha positive and express progesterone receptor, although at reduced level compared to parental T7D/S2 cells. T47D/TR-1 are growth inhibited by fulvestrant. Passage 164 (AL3569, AL3570) |
| Cellosaurus ID | CVCL_1D36 |
References: 8 entries
Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.
Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.
Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Europe PMC ID: 25885472
SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
Europe PMC ID: 25706943
Thrane et al. 2014. Oncogene. :. PMID: 25362855.
A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Europe PMC ID: 25362855
Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.
T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.
Europe PMC ID: 24513268
Add a reference
References: 8 entries
Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.
Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.
Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
Thrane et al. 2014. Oncogene. :. PMID: 25362855.
A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.
T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.
Add a reference
